HONG KONG – Y-biologics Inc., a South Korean biopharmaceutical firm, and U.S.-based biotechnology venture Genosco Inc. have recently signed a contract for cancer drugs research and development focused on testing the combination of immune checkpoint inhibitors and small-molecule cancer drugs.